United Therapeutics Corporation $UTHR Stake Raised by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 19.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,076 shares of the biotechnology company’s stock after acquiring an additional 1,321 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $4,376,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in UTHR. BOKF NA boosted its holdings in shares of United Therapeutics by 12.3% during the 3rd quarter. BOKF NA now owns 7,834 shares of the biotechnology company’s stock valued at $4,245,000 after buying an additional 857 shares in the last quarter. Asset Management One Co. Ltd. grew its position in shares of United Therapeutics by 1.9% in the 3rd quarter. Asset Management One Co. Ltd. now owns 23,166 shares of the biotechnology company’s stock worth $12,553,000 after buying an additional 424 shares during the period. Kingswood Wealth Advisors LLC grew its position in shares of United Therapeutics by 8.7% in the 3rd quarter. Kingswood Wealth Advisors LLC now owns 628 shares of the biotechnology company’s stock worth $340,000 after buying an additional 50 shares during the period. Citizens Financial Group Inc. RI increased its stake in shares of United Therapeutics by 26.5% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 912 shares of the biotechnology company’s stock worth $494,000 after acquiring an additional 191 shares in the last quarter. Finally, One Wealth Capital Management LLC bought a new position in shares of United Therapeutics in the 3rd quarter worth about $323,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $585.49, for a total value of $5,562,155.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $189,958,132.07. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $24,587,119.60. This represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 401,528 shares of company stock valued at $210,097,491 over the last quarter. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 1.2%

United Therapeutics stock opened at $593.54 on Friday. United Therapeutics Corporation has a 12 month low of $430.02 and a 12 month high of $609.35. The stock has a fifty day simple moving average of $525.55 and a two-hundred day simple moving average of $529.96. The firm has a market cap of $25.46 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 4.25 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the company posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has authorized a share buyback plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 8.3% of its shares through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA cleared United Therapeutics to begin a clinical trial of its inhaled treprostinil-iloprost combination therapy, or Treprostinil-Iloprost SMI, for pulmonary arterial hypertension. The approval allows the company to advance a potentially important pipeline product alongside its established PAH franchise, although clinical efficacy and commercialization remain unproven. United Therapeutics Cleared To Start Trial For New Pulmonary Hypertension Therapy
• Positive Sentiment: The company’s board recently authorized a $2 billion share-repurchase program, equivalent to as much as 8.3% of outstanding shares. Buybacks can support earnings per share and signal management’s confidence that the stock is undervalued.
• Neutral Sentiment: JPMorgan maintained an “overweight” rating but reduced its price target from $710 to $695, still implying meaningful potential appreciation from recent trading levels. Analysts overall retain a Moderate Buy consensus, with an average target of $666.50.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.6 million, reducing her direct ownership by 2.84%. The sale is relatively small compared with her remaining stake, but insider selling can create a modest sentiment overhang. SEC insider transaction filing
• Negative Sentiment: Investors are approaching the next earnings report amid expectations for declining earnings, while the company’s latest reported revenue fell 1.9% year over year and missed consensus despite an EPS beat. That combination could limit near-term upside if results or guidance disappoint.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Morgan Stanley raised their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. UBS Group set a $725.00 target price on shares of United Therapeutics in a report on Monday, October 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research report on Monday. Finally, JPMorgan Chase & Co. cut their price target on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research note on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $667.07.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.